ASH 2025 | MRD as a surrogate endpoint in NPM1-mutated AML: implications for clinical trials and regulation
Farhad Ravandi
• 5 Dec 2025
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights a pooled analysis evaluating measurable residual disease (MRD) as a surrogate endpoint in NPM1-mutated acute myeloid leukemia (AML), with potential implications for accelerating clinical trials and regulatory decision-making. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
